Both in Pharmaceuticals
Aprea Therapeutics vs Longeveron
Over the past year APRE returned −62.1% and LGVN returned −80.8%; their daily moves had a correlation of 0.11.
APRE −62.1% LGVN −80.8%Growth of $1, one year, split-adjusted
| Metric | APRE | LGVN |
|---|---|---|
| Price | $0.5363 | $1.77 |
| Market cap | $6.8M | $5.6M |
| Today | +4.54% | +2.31% |
| 1 month | −30.3% | −34.9% |
| 6 months | −34.5% | −79.5% |
| Year to date | −37.1% | −65.0% |
| 1 year | −60.0% | −80.7% |
| Revenue growth (YoY) | −100.0% | −9.2% |
| Gross margin | — | 63.4% |
| Net margin | — | −2116.0% |
| P/E (TTM) | — | — |
| Price / sales | 1,302.3× | 4.8× |
| Net cash | $41.2M | $10.1M |
| Dividend yield | — | — |
| Volatility (60d) | 94.4% | 708.8% |
| Short % of float | 5.9% | 2.8% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).